Literature DB >> 11173045

Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.

F Buttgereit1, G R Burmester, L S Simon.   

Abstract

Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation but are frequently associated with gastrointestinal side effects, including life-threatening bleeding or perforation of gastroduodenal ulcers. Conventional NSAIDs are nonselective inhibitors of two isoforms of cyclooxygenase (COX): COX-1 and COX-2. The inhibition of COX-1 is believed to be responsible for inducing mucosal injury primarily by impairing prostaglandin-dependent mucosal protective mechanisms. The latest development in reducing the incidence of ulcers and ulcer complications associated with conventional NSAIDs is the use of recently approved COX-2-specific inhibitors (CSIs). This article critically reviews the data on gastrointestinal toxic side effects for conventional NSAIDs without as well as with prevention therapy. In addition, we compare these data with those for the CSIs, namely, celecoxib and rofecoxib. Finally, we offer recommendations on the clinical use of these drugs, emphasizing the need to balance clinical effectiveness with the avoidance of potential gastrointestinal side effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11173045     DOI: 10.1016/s0002-9343(00)00728-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

1.  Immediate changes in temporomandibular joint opening and pain following vibration therapy: a feasibility pilot study.

Authors:  Brad Muir; Courtney Brown; Tara Brown; Dionne Tatlow; Jeremy Buhay
Journal:  J Can Chiropr Assoc       Date:  2014-12

2.  A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.

Authors:  Nobuyuki Sugisaki; Ryuichi Iwakiri; Nanae Tsuruoka; Yasuhisa Sakata; Ryo Shimoda; Shun Fujimoto; Yuichiro Eguchi; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2018-06-12       Impact factor: 7.527

Review 3.  The Role of Alpha-2 Adrenergic Receptors in Anti-ulcer Activity.

Authors:  Halis Suleyman
Journal:  Eurasian J Med       Date:  2012-04

4.  Evaluation of the Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects of Withaferin A (WA) against Lipopolysaccharide (LPS)-Induced Inflammation in Immune Cells Derived from BALB/c Mice.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed Almutary; Gh Rasool Bhat; Tanveer Ahmad Mir; Shadil Ibrahim Wani; Mohd Younis Rather; Shabir Ahmad Mir; Bader Alshehri; Sulaiman Alnasser; Faten M Ali Zainy; Bilal Rah
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

5.  Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.

Authors:  Marc Ouellet; Jean-Pierre Falgueyret; M David Percival
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

Review 6.  Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers.

Authors:  Halis Suleyman; Abdulmecit Albayrak; Mehmet Bilici; Elif Cadirci; Zekai Halici
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

7.  Design, synthesis, and discovery of 5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones and related derivatives as novel inhibitors of mPGES-1.

Authors:  Kai Ding; Ziyuan Zhou; Shuo Zhou; Yaxia Yuan; Kyungbo Kim; Ting Zhang; Xirong Zheng; Fang Zheng; Chang-Guo Zhan
Journal:  Bioorg Med Chem Lett       Date:  2018-02-08       Impact factor: 2.823

8.  Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study).

Authors:  Peter Rose; Christine Steinhauser
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

9.  Sex-dependent effect of cyclooxygenase-2 inhibition on mouse spatial memory.

Authors:  Cristina B Guzmán; Kaylan A Graham; Lindsey A Grace; Amy H Moore
Journal:  Behav Brain Res       Date:  2009-01-08       Impact factor: 3.332

10.  First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

Authors:  Ralf H Wittenberg; Ernest Schell; Gerhard Krehan; Roland Maeumbaed; Hans Runge; Peter Schlüter; Taiwo O A Fashola; Helen J Thurston; Klaus J Burger; Ulrich Trechsel
Journal:  Arthritis Res Ther       Date:  2006-01-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.